Evofem posts $18.2M Phexxi net sales in 2023; operating loss improves 79% YoY; Aditxt acquisition pending

Evofem Biosciences, Inc.

Net product sales $18.2M, up from $16.8M in 2022; Q4 sales $4.8M vs $0.2M.
Total operating expenses reduced 64% to $36.1M from $101.0M; selling and marketing down 73%.
Loss from operations improved to $17.8M from $84.1M (79% improvement).
Entered definitive agreement to be acquired by Aditxt (ADTX); expected closing H2 2024.
Cash: $0.6M restricted at Dec 2023; compared to $2.8M unrestricted at Dec 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Evofem Biosciences, Inc. reported year ended December 31, 2023 results: revenue $18.2 million.

Period: year ended December 31, 2023
Revenue: $18.2 million
Result: reported results

Exact text from the filing

For the year ended December 31, 2023, net product sales were $18.2 million compared to $16.8 million in net product sales in the prior year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

Evofem Biosciences, Inc. reported three months ended December 31, 2023 results: revenue $4.8 million.

Period: three months ended December 31, 2023
Revenue: $4.8 million
Result: reported results

Exact text from the filing

For the three months ended December 31, 2023, net product sales were $4.8 million compared to $0.2 million in the prior year period.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.